Nyrada Inc (ASX:NYR) is a new US registered, Australia domiciled pharmaceutical company. Our business is drug discovery and drug development in areas of significant community need in the cardiovascular and neurology fields. Our clinical targets are diseases and conditions affecting large numbers of individuals, where current treatment options are suboptimal, and in some cases, non-existent. The guiding principles driving our commercial strategies are: • Sound scientific rationale • Significant unmet clinical need • Large market opportunity • Low number of competitors • Strong IP protection • Favourable regulatory pathway to approval Nyrada’s two main programmes are a cholesterol-lowering drug and a drug to treat brain injury, specifically stroke and traumatic brain injury (TBI).